Drug Profile

Pertussis acellular vaccine low-dose - GlaxoSmithKline

Alternative Names: GSK-251154; Reduced antigen content tri-component acellular pertussis vaccine - GlaxoSmithKline

Latest Information Update: 25 Feb 2014

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Class Bacterial vaccines; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Pertussis

Most Recent Events

25 Feb 2012 Discontinued - Phase-II for Pertussis in Belgium (IM)
25 Feb 2012 Discontinued - Phase-II for Pertussis in Netherlands (IM)
03 May 2010 Phase-II clinical trials in Pertussis in Belgium (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com